Aerpio Pharmaceuticals, Inc. (ARPO): Price and Financial Metrics


Aerpio Pharmaceuticals, Inc. (ARPO): $33.00

-0.30 (-0.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARPO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARPO Stock Price Chart Interactive Chart >

Price chart for ARPO

ARPO Price/Volume Stats

Current price $33.00 52-week high $34.50
Prev. close $2.22 52-week low $0.95
Day low $32.40 Volume 55,066
Day high $34.50 Avg. volume 5,147,753
50-day MA $2.04 Dividend yield N/A
200-day MA $1.64 Market Cap 1.57B

Aerpio Pharmaceuticals, Inc. (ARPO) Company Bio


Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is based in Cincinnati, Ohio


ARPO Latest News Stream


Event/Time News Detail
Loading, please wait...

ARPO Latest Social Stream


Loading social stream, please wait...

View Full ARPO Social Stream

Latest ARPO News From Around the Web

Below are the latest news stories about Aerpio Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARPO as an investment opportunity.

Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

LOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under ARPO).

Intrado Digital Media | August 26, 2021

Earnings Report: Heres what to expect from Aerpio Pharmaceuticals (NASDAQ:ARPO)

Earnings results for Aerpio Pharmaceuticals , Analyst Opinion on Aerpio Pharmaceuticals , Earnings and Valuation of (NASDAQ:ARPO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Earnings Report: Heres what to expect from Aerpio Pharmaceuticals (NASDAQ:ARPO) appeared first on .

Stock Market Daily | August 11, 2021

Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update

CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Aerpio) (Nasdaq: ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update.

Intrado Digital Media | August 11, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | July 12, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | July 10, 2021

Read More 'ARPO' Stories Here

ARPO Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 25.00%
3-year 146.66%
5-year N/A
YTD N/A
2021 0.00%
2020 57.18%
2019 -63.32%
2018 -64.21%
2017 N/A

Continue Researching ARPO

Here are a few links from around the web to help you further your research on Aerpio Pharmaceuticals Inc's stock as an investment opportunity:

Aerpio Pharmaceuticals Inc (ARPO) Stock Price | Nasdaq
Aerpio Pharmaceuticals Inc (ARPO) Stock Quote, History and News - Yahoo Finance
Aerpio Pharmaceuticals Inc (ARPO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5986 seconds.